DoD Gulf War Illness, New Investigator Award | W81XWH 21 GWIRP NIA

Opportunity Information: Apply for W81XWH 21 GWIRP NIA

The DoD Gulf War Illness Research Program (GWIRP) New Investigator Award (FY21) is a research funding opportunity intended to bring new people and new ideas into the Gulf War Illness (GWI) field. It is specifically set up so investigators who are not yet established GWI researchers can compete in a separate pool from long-standing GWI programs, with the goal of helping early-stage or newly entering investigators generate strong proof-of-principle results that can grow into larger, future studies. The work can range from basic science through clinical research, but it must stay focused on GWI and on Veterans from the 1990-1991 Gulf War who are affected by GWI.

Eligibility is organized around the career status of the Principal Investigator (PI). Applicants must qualify under one of three categories described in the full announcement: Transitioning Postdoctoral Fellow, Early-Career Investigator, or New GWI Researcher. Prior experience in GWI research is allowed but not required. If the PI has limited GWI background, the program strongly encourages building collaborations with investigators who do have GWI experience and/or other key expertise. The application is expected to explain how those collaborators will directly strengthen the PI's ability to answer the research question (for example, by adding GWI cohort access, specialized assays, clinical phenotyping capability, or established analytical methods).

The award is designed for discovery and early validation work, where the emphasis is on testing innovative hypotheses, exploring mechanisms, or establishing feasibility rather than delivering a fully mature clinical intervention. Preliminary data are optional. Applicants can include preliminary findings if they have them, and those data do not have to come from the GWI field. If no preliminary data are provided, the proposal is still acceptable as long as it is grounded in a solid scientific rationale, which could include clinical observations or findings from other illnesses with symptoms relevant to GWI. Regardless of approach, the application must clearly describe how the expected results could eventually lead to clinical impact for Veterans with GWI, even if that impact is not immediate within the proposed project period.

The FY21 program lists several areas of emphasis where it has special interest, while still allowing applicants to propose other GWI-relevant topics consistent with GWIRP priorities. Priority themes include identifying, replicating, and validating treatments for GWI, especially where there are already promising signals; rapidly translating newly emerging biological understanding into actionable research directions; and clarifying causes, mechanisms, and treatment targets tied to dysregulated biological system function. Within that systems-dysfunction theme, examples of high-interest symptom or domain areas include cognitive problems (memory deficits and related mood/behavior disturbance), non-restorative sleep and sleep disruption, chronic widespread pain, chronic debilitating fatigue, gastrointestinal effects (dietary intolerances, GERD, and functional GI disorders), sinus and respiratory effects, headaches, dermatological issues, neurological dysfunction (central, peripheral, autonomic, and/or neuromuscular), immune dysfunction, and endocrine/exocrine/excretory dysfunction with particular attention to kidney and liver issues (including cytochrome P450 abnormalities). The announcement also highlights interest in microbiome variants, the way stressors like exertion or immune challenges change symptom severity and duration, and disordered crosstalk between systems (such as immune changes that affect the nervous system or autonomic dysfunction that alters GI function). Additional emphasis areas include identifying molecular signatures (genomic, proteomic, metabolic, epigenetic) that may underlie symptoms and help cluster Veterans into biologically meaningful subgroups; studying comorbidities, mortality, and sex or ethnic differences; examining whether GWI changes outcomes of other infections or diseases; and developing treatments and biomarkers for specific GWI subtypes.

A notable feature of this funding opportunity is an optional Biorepository Contribution Option tied to the Boston Biorepository, Recruitment, and Integrative Network (BBRAIN) for GWI. Applicants are encouraged to contribute Gulf War Veteran biospecimens and/or associated data to this established repository to support broader research progress. Proposals that qualify and apply under this option can request a slightly higher direct-cost limit and must meet additional submission requirements described in the announcement (including a specific biorepository contribution statement).

The program also states clear boundaries on what it will not support. It does not support studies that frame psychiatric disease or psychological stress as the primary cause of GWI. It does not support ALS-focused research, although projects centered on GWI symptomatology may include Gulf War Veterans with ALS if ALS is part of the study's GWI case definition. It also does not support clinical trials under this mechanism; clinical trials are defined in the standard way as studies prospectively assigning human subjects to interventions to evaluate health-related outcomes. Investigators who want to run clinical trials are directed instead to other GWIRP mechanisms such as the Clinical Evaluation Award or the Therapeutic/Biomarker Trial Award.

Awards are issued as assistance agreements, meaning the funding will be provided as either a grant or a cooperative agreement depending on the expected level of DoD involvement during the project. If substantial involvement by the DoD is anticipated (such as collaboration or participation in the research effort), a cooperative agreement would be used; otherwise, a standard grant would be issued. The award type and start date are finalized during negotiations.

On the funding side, the anticipated maximum direct costs for the full period of performance are capped at $500,000, or $520,000 if using the Biorepository Contribution Option. The program expected to allocate about $800,000 total and make approximately one award, with final funding dependent on federal fund availability and the scientific and programmatic merit of applications. Key dates in the posted opportunity include a creation date of March 11, 2021 and an original application closing date of August 19, 2021, with awards anticipated no later than September 30, 2022. The opportunity is administered by the Department of Defense (Department of the Army, USAMRAA) under CFDA 12.420, and eligibility is listed as unrestricted by entity type (subject to the detailed eligibility rules for PI status described in the full announcement).

• The Department of Defense, Dept. of the Army -- USAMRAA in the science and technology and other research and development sector is offering a public funding opportunity titled "DoD Gulf War Illness, New Investigator Award" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 12.420.
• This funding opportunity was created on Mar 11, 2021.
• Applicants must submit their applications by Aug 19, 2021. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• The number of recipients for this funding is limited to 1 candidate(s).
• Eligible applicants include: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled Additional Information on Eligibility.

Apply for W81XWH 21 GWIRP NIA

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: